Geron Corp (GERN) stock
GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.00+0.06 (+6.17%)
Close on Nov 17, 2026Market cap $642.47MP/E –Yield –
Geron r&d expenses
Research and development expenses are spending on new products and technology.
Geron's R&D Expenses for the twelve months ending Jun 30, 2026 was $71.61M, down 10.9% year over year. For fiscal 2025 it was $71.43M, down 31.1% from the year before. Over ten years it grew 14.9% a year on average. The highest annual figure on record is $125.05M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.43M | -31.1% |
| FY2024 | Dec 31, 2024 | $103.74M | -17.0% |
| FY2023 | Dec 31, 2023 | $125.05M | +30.9% |
| FY2022 | Dec 31, 2022 | $95.52M | +11.4% |
| FY2021 | Dec 31, 2021 | $85.73M | +66.5% |
| FY2020 | Dec 31, 2020 | $51.49M | -1.1% |
| FY2019 | Dec 31, 2019 | $52.07M | +287.7% |
| FY2018 | Dec 31, 2018 | $13.43M | +21.7% |
| FY2017 | Dec 31, 2017 | $11.03M | -38.9% |
| FY2016 | Dec 31, 2016 | $18.05M | +1.2% |
| FY2015 | Dec 31, 2015 | $17.83M | -13.9% |
| FY2014 | Dec 31, 2014 | $20.71M | -10.6% |
| FY2013 | Dec 31, 2013 | $23.16M | -54.9% |
| FY2012 | Dec 31, 2012 | $51.37M | -25.9% |
| FY2011 | Dec 31, 2011 | $69.32M | +12.4% |
| FY2010 | Dec 31, 2010 | $61.69M | +7.1% |
| FY2009 | Dec 31, 2009 | $57.62M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.03M | +1.4% |
| Q1 FY2026 | Mar 31, 2026 | $14.96M | -0.8% |
| Q4 FY2025 | Dec 31, 2025 | $13.55M | -42.2% |
| Q3 FY2025 | Sep 30, 2025 | $21.07M | +4.6% |
| Q2 FY2025 | Jun 30, 2025 | $21.74M | -29.4% |
| Q1 FY2025 | Mar 31, 2025 | $15.08M | -48.7% |
| Q4 FY2024 | Dec 31, 2024 | $23.43M | -28.8% |
| Q3 FY2024 | Sep 30, 2024 | $20.15M | -31.5% |
| Q2 FY2024 | Jun 30, 2024 | $30.78M | -13.3% |
| Q1 FY2024 | Mar 31, 2024 | $29.37M | +7.9% |
| Q4 FY2023 | Dec 31, 2023 | $32.91M | +16.7% |
| Q3 FY2023 | Sep 30, 2023 | $29.43M | +19.6% |
| Q2 FY2023 | Jun 30, 2023 | $35.49M | +72.2% |
| Q1 FY2023 | Mar 31, 2023 | $27.22M | +23.2% |
| Q4 FY2022 | Dec 31, 2022 | $28.21M | +16.8% |
| Q3 FY2022 | Sep 30, 2022 | $24.60M | +32.8% |
| Q2 FY2022 | Jun 30, 2022 | $20.61M | -6.1% |
| Q1 FY2022 | Mar 31, 2022 | $22.10M | +4.7% |
| Q4 FY2021 | Dec 31, 2021 | $24.15M | +48.8% |
| Q3 FY2021 | Sep 30, 2021 | $18.53M | +36.1% |
| Q2 FY2021 | Jun 30, 2021 | $21.94M | +102.3% |
| Q1 FY2021 | Mar 31, 2021 | $21.11M | +95.5% |
| Q4 FY2020 | Dec 31, 2020 | $16.23M | -34.9% |
| Q3 FY2020 | Sep 30, 2020 | $13.61M | +22.5% |
| Q2 FY2020 | Jun 30, 2020 | $10.85M | +7.0% |
| Q1 FY2020 | Mar 31, 2020 | $10.80M | +82.9% |
| Q4 FY2019 | Dec 31, 2019 | $24.92M | +390.5% |
| Q3 FY2019 | Sep 30, 2019 | $11.11M | +310.4% |
| Q2 FY2019 | Jun 30, 2019 | $10.13M | +216.3% |
| Q1 FY2019 | Mar 31, 2019 | $5.91M | +142.0% |
| Q4 FY2018 | Dec 31, 2018 | $5.08M | +101.4% |
| Q3 FY2018 | Sep 30, 2018 | $2.71M | +2.7% |
| Q2 FY2018 | Jun 30, 2018 | $3.20M | +28.2% |
| Q1 FY2018 | Mar 31, 2018 | $2.44M | -27.7% |
| Q4 FY2017 | Dec 31, 2017 | $2.52M | -38.8% |
| Q3 FY2017 | Sep 30, 2017 | $2.64M | -38.9% |
| Q2 FY2017 | Jun 30, 2017 | $2.50M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.37M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.12M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.32M | – |
See a number that looks wrong?